Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE

Brain

Volumn 129, Issue 12, 2006, Pages 3196-3208

  Black, Joel A ^a,b   Liu, Shujun ^a,b   Hains, Bryan C ^a,b   Saab, Carl Y ^c   Waxman, Stephen G ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

Axon protection; EAE; Inflammatory cell; Multiple sclerosis; Phenytoin; Sodium channel

Indexed keywords

FLECAINIDE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PHENYTOIN; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT;

ACTION POTENTIAL; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; ELECTROPHYSIOLOGY; HOMEOSTASIS; IMAGE ANALYSIS; INFLAMMATORY CELL; MOUSE; MOUSE STRAIN; NERVE FIBER DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PYRAMIDAL TRACT; RECURRENT DISEASE; SCORING SYSTEM; SURVIVAL TIME;

ACTION POTENTIALS; ADMINISTRATION, ORAL; ANIMALS; AXONS; CELL COUNT; CERVICAL VERTEBRAE; CHRONIC DISEASE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNOHISTOCHEMISTRY; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED C57BL; MYELIN-ASSOCIATED GLYCOPROTEIN; NEURAL CONDUCTION; PHENYTOIN; RECURRENCE; SODIUM CHANNEL BLOCKERS; SPINAL CORD; TREATMENT OUTCOME;

EID: 33751166454     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awl216     Document Type: Article

References (49)

1. 2+ exchanger. J Neurosci 1996; 16: 545-52.
2. Agrawal SK, Fehlings MG. The effect of the sodium channel blocker QX-314 on recovery after acute spinal cord injury. J Neurotrauma 1997; 14: 81-8.
3. Anthony DC, Miller KM, Fearn S, Townsend MJ, Opdenakker G, Wells GM, et al. Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS. J Neuroimmunol 1998; 87: 62-72.
4. Bechtold DA, Kapoor R, Smith KJ. Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann Neurol 2004; 55: 607-16.
5. Bechtold DA, Smith KY. Sodium-mediated axonal degeneration in inflammatory demyelinating disease. J Neurol Sci 2005; 233: 27-35.
6. Bjartmar C, Kidd G, Mork S, Rudick R, Trapp BD. Neurological disability correlates with spinal cord axonal loss and reduce N-acetyl-aspartate in chronic mutliple sclerosis patients. Ann Neurol 2000; 48: 893-901.
7. Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 2003; 206: 165-71.
8. Bo L, Dawson TM, Wesselingh S, Mork S, Choi S, Kong PA, et al. Induction of nitric oxide synthetase in demyelinating regions of multiple sclerosis. Ann Neurol 2000; 36: 893-900.
9. Bolanos JP, Almeida A, Stewart V, Peuchen S, Land JM, Clark JB, et al. Nitric oxide-mediated mitochondrial damage in the brain: mechanisms and implications for neurodegenerative diseases. J Neurochem 1997; 68: 2227-40.
10. Brand-Schieber E, Werner P. Calcium channel blockers ameliorate disease in a mouse model of multiple sclerosis. Exp Neurol 2004; 189: 5-9.
11. Brosnan CF, Battistini L, Raine C, Dickson DW, Casadevall A. Reactive nitrogen intermediates in human pathology: an overview. Dev Neurosci 1994; 16: 152-61.
12. Craner MJ, Hains BC, Lo AC, Black JA, Waxman SG. Co-localization of sodium channel Nav1.6 and the sodium-calcium exchanger at sites of axonal injury in the spinal cord in EAE. Brain 2004a; 127: 294-303.
13. Craner MJ, Newcombe J, Black JA, Hartle C, Cuzner ML, Waxman SG. Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger. Proc Natl Acad Sci USA 2004b; 101: 8168-73.
14. Craner MJ, Damarjian TG, Liu S, Hains BC, Lo AC, Black JA, et al. Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. Glia 2005; 49: 220-9.
15. Davie C, Barker G, Webb S, Tofts P, Thompson A, Harding A, et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axonal loss. Brain 1995; 118: 1583-92.
16. Diem R, Sattler MB, Merkler D, Demmer I, Maier K, Stadelmann C, et al. Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain 2005; 128: 375-85.
17. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393-9.
18. Fern R, Ransom BR, Stys PK, Waxman SG. Pharmacological protection of CNS white matter during anoxia: actions of phenytoin, carbamazepine, and diazepam. J Pharmacol Exp Ther 1993; 266: 1549-55.
19. Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G, et al. Glatiramer acetate reduces the proportion of new MS lesions evolving into 'black holes'. Neurology 2001; 57: 731-3.
20. Gilgun-Sherki Y, Panet H, Holdengreber V, Mosberg-Galili R, Offen D. Axonal damage is reduced following glatiramer acetate treatment in C57/bl mice with chronic-induced experimental autoimmune encephalomyelitis. Neurosci Res 2003; 47: 201-7.
21. Gold BG, Voda J, Yu X, McKeon G, Bourdette DN. FK506 and a non-immunosuppressant derivative reduce axonal and myelin damage in experimental autoimmune encephalomyelitis: neuroimmunophilin ligand-mediated neuroprotection in a model of multiple sclerosis. J Neurosci Res 2004; 77: 367-77.
22. Hains BC, Saab CY, Lo AC, Waxman SG. Sodium channel blockade with phenytoin protects spinal cord axons, enhances axonal conduction, and improves functional motor recovery after contusion SCI. Exp Neurol 2004; 188: 365-77.
23. Jacobsen M, Cepok S, Quak E, Happel M, Gaber R, Ziegler A, et al. Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain 2002; 125: 538-50.
24. Kapoor R, Davies M, Blaker PA, Hall SM, Smith KJ. Blockers of sodium and calcium entry protect axons from nitric-oxide mediated degeneration. Ann Neurol 2003; 53: 174-80.
25. Korotzer AR, Cotman CW. Voltage-gated currents expressed by rat microglia in culture. Glia 1992; 6: 81-8.
26. Kornek B, Storch MK, Weissert R, Wallstroem E, Stefferl A, Olsson T, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 2000; 157: 267-76.
27. Kuhlman T, Lingfield G, Birsch A, Schuchardt J, Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002; 125: 2202-12.
28. Lee MA, Blamire AM, Pendlebury S, Ho KH, Mills KR, Styles P, et al. Axonal injury or loss in the internal capsule and motor impairment in multiple sclerosis. Arch Neurol 2000; 57: 65-70.
29. Li H, Cuzner ML, Newcombe J. Microglia-derived macrophages in early multiple sclerosis plaques. Neuropathol Appl Neurobiol 1996; 22: 207-15.
30. Li W, Maeda Y, Yaun RR, Elkabes S, Cook S, Dowling P. Beneficial effect of erythropietin on experimental allergic encephalomyelitis. Ann Neurol 2004; 56: 767-77.
31. Lo AC, Black JA, Waxman SG. Neuroprotection of axons with phenytoin in experimental allergic encephalomyelitis. NeuroReport 2002; 13: 1909-12.
32. Lo AC, Saab CY, Black JA, Waxman SG. Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. J Neurophysiol 2003; 90: 3566-71.
33. Norenberg W, Illes P, Gebicke-Haerter PJ. Sodium channels in isolated human brain macrophages (microglia). Glia 1994; 10: 165-72.
34. Ragsdale DS, Avoli M. Sodium channels as molecular targets for antiepileptic drugs. Brain Res Rev 1998; 26: 16-28.
35. + channels. Proc Natl Acad Sci USA 1996; 93: 9270-5.
36. Renno T, Krakowski M, Piccirillo C, Lin JY, Owens T. TNF-alpha expression by resident microglia and infiltrating leukocytes in the central nervous system of mice with experimental allergic encephalomyelitis. Regulation by Th1 cytokines. J Immunol 1995; 154: 944-53.
37. Rosenberg LJ, Teng YD, Wrathall JR. Effects of the sodium channel blocker tetrodotoxin on acute white matter pathology after experimental contusive spinal cord injury. J Neurosci 1999; 19: 6122-33.
38. v1.6, expressed in mouse spinal sensory neurones. J Physiol 2005; 564: 803-15.
39. Schmidtmayer J, Jacobsen C, Miksch G, Sievers J. Blood monocytes and spleen macrophages differentiate into microglia-like cells on monolayers of astrocytes: membrane currents. Glia 1994; 12: 259-67.
40. Smith KJ, Kapoor R, Felts PA. Demyelination: the role of reative oxygen and nitrogen species. Brain Pathol 1999; 9: 69-92.
41. Smith KJ, Lassmann H. The role of nitric oxide in multiple sclerosis. Lancet Neurol 2002; 1: 232-41.
42. Stys PK, Lopachin RM. Mechanisms of calcium and sodium fluxes in anoxic myelinated central nervous system axons. Neurosci 1998; 82: 21-32.
43. 2+ exchanger. J Neurosci 1992; 12: 430-9.
44. Stys PK, Sontheimer H, Ransom BR, Waxman SG. Noninactivating, tetrodotoxin-sensitive Na+ conductance in rat optic nerve. Proc Natl Acad Sci USA 1993; 90: 6976-80.
45. Teng YD, Wrathall JR. Local blockade of sodium channels by tetrodotoxin ameliorates tissue loss and long-term functional deficits resulting from experimental spinal cord injury. J Neurosci 1997; 17: 4359-66.
46. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85.
47. Waxman SG, Ransom BR, Stys PK. Non-synaptic mechanisms of Ca(2+)-mediated injury in CNS white matter. Trends Neurosci 1991; 14: 461-8.
48. White SR, Black PC, Samathanam GK, Paros KC. Prazosin suppresses development of axonal damage in rats inoculated for experimental allergic encephalomyelitis. J Neuroimmunol 1992; 39: 211-8.
49. Wujek JR, Bjartmar C, Richer E, Ransohoff RM, Yu M, Tuohy VK, et al. Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J Neuropathol Exp Neurol 2002; 61: 23-32.